BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zafatek (Trelagliptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zafatek (Trelagliptin)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07073768-305@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:Zafatek (Trelagliptin): Phase 3 readout est. (NCT07073768)
DESCRIPTION:Zafatek (Trelagliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Com
 parison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabet
 ic Patients\nEstimated primary completion: 26 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trelagliptin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07073768
URL:https://assetmemo.bio/drug/trelagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
